Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Myeloproliferative Neoplasm

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

FIP1L1-PDGFRA fusion	Chronic Eosinophilic Leukemia	FIP1L1-PDGFRA fusion	Chronic Eosinophilic Leukemia	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
CSF3R T618I	Chronic Neutrophilic Leukemia	CSF3R T618I	Chronic Neutrophilic Leukemia	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3
KIT M541L	Chronic Eosinophilic Leukemia	KIT M541L	Chronic Eosinophilic Leukemia	imatinib Sensitive: C3 – Early Trials imatinib Sensitive : C3	imatinib Sensitive: C3 – Early Trials imatinib Sensitive : C3
PCM1-JAK2 fusion	Chronic Eosinophilic Leukemia	PCM1-JAK2 fusion	Chronic Eosinophilic Leukemia	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3
FIP1L1-PDGFRA fusion	Chronic Eosinophilic Leukemia	FIP1L1-PDGFRA fusion	Chronic Eosinophilic Leukemia	YD312 Sensitive: C4 – Case Studies YD312 Sensitive : C4	YD312 Sensitive: C4 – Case Studies YD312 Sensitive : C4
CSF3R S783	Chronic Neutrophilic Leukemia	CSF3R S783	Chronic Neutrophilic Leukemia	dasatinib Sensitive: D – Preclinical dasatinib Sensitive : D	dasatinib Sensitive: D – Preclinical dasatinib Sensitive : D
CSF3R T618I	Chronic Neutrophilic Leukemia	CSF3R T618I	Chronic Neutrophilic Leukemia	dasatinib Resistant: D – Preclinical dasatinib Resistant : D	dasatinib Resistant: D – Preclinical dasatinib Resistant : D